DK1202733T3 - 3(5)-amino-pyrazolderivater, fremgangsmåde til deres fremstilling og deres anvendelse som antitumormidler - Google Patents
3(5)-amino-pyrazolderivater, fremgangsmåde til deres fremstilling og deres anvendelse som antitumormidlerInfo
- Publication number
- DK1202733T3 DK1202733T3 DK00931906T DK00931906T DK1202733T3 DK 1202733 T3 DK1202733 T3 DK 1202733T3 DK 00931906 T DK00931906 T DK 00931906T DK 00931906 T DK00931906 T DK 00931906T DK 1202733 T3 DK1202733 T3 DK 1202733T3
- Authority
- DK
- Denmark
- Prior art keywords
- amino
- preparation
- antitumor agents
- pyrazole derivatives
- pyrazole
- Prior art date
Links
- JVVRJMXHNUAPHW-UHFFFAOYSA-N 1h-pyrazol-5-amine Chemical class NC=1C=CNN=1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/16—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37283199A | 1999-08-12 | 1999-08-12 | |
PCT/US2000/006699 WO2001012189A1 (en) | 1999-08-12 | 2000-05-05 | 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1202733T3 true DK1202733T3 (da) | 2005-10-31 |
Family
ID=23469802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK00931906T DK1202733T3 (da) | 1999-08-12 | 2000-05-05 | 3(5)-amino-pyrazolderivater, fremgangsmåde til deres fremstilling og deres anvendelse som antitumormidler |
Country Status (35)
Country | Link |
---|---|
US (2) | US7034049B1 (et) |
EP (1) | EP1202733B1 (et) |
JP (1) | JP2003507329A (et) |
KR (1) | KR20020060160A (et) |
CN (1) | CN1373662A (et) |
AP (1) | AP2002002442A0 (et) |
AR (1) | AR026122A1 (et) |
AT (1) | ATE305782T1 (et) |
AU (1) | AU4971400A (et) |
BG (1) | BG106480A (et) |
BR (1) | BR0013143A (et) |
CA (1) | CA2383555C (et) |
CZ (1) | CZ2002422A3 (et) |
DE (1) | DE60023012T2 (et) |
DK (1) | DK1202733T3 (et) |
EA (1) | EA005373B1 (et) |
EE (1) | EE200200065A (et) |
ES (1) | ES2249270T3 (et) |
GE (1) | GEP20053476B (et) |
HK (1) | HK1046866A1 (et) |
HR (1) | HRP20020128A2 (et) |
HU (1) | HUP0203542A3 (et) |
IL (1) | IL147923A0 (et) |
IS (1) | IS6265A (et) |
MA (1) | MA25493A1 (et) |
MX (1) | MXPA02001498A (et) |
NO (1) | NO20020684L (et) |
NZ (1) | NZ517237A (et) |
OA (1) | OA12046A (et) |
PE (1) | PE20010130A1 (et) |
PL (1) | PL353455A1 (et) |
SK (1) | SK1812002A3 (et) |
WO (1) | WO2001012189A1 (et) |
YU (1) | YU9602A (et) |
ZA (1) | ZA200201511B (et) |
Families Citing this family (157)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9901691D0 (en) | 1999-01-26 | 1999-03-17 | Cerebrus Ltd | Chemical compounds |
OA12046A (en) * | 1999-08-12 | 2006-05-02 | Pharmacia Italia Spa | 3(5)-Amino-pyrazole derivatives, process for theirpreparation and their use as antitumor agents. |
JP2003522174A (ja) | 2000-02-07 | 2003-07-22 | ブリストル−マイヤーズ スクイブ カンパニー | サイクリン依存性キナーゼの3−アミノピラゾール阻害剤 |
ES2236217T3 (es) | 2000-04-25 | 2005-07-16 | Bristol-Myers Squibb Company | Uso de 5.tio.,sulfinil- y sulfonilpirazolo 3,4-b)-piridinas como inhibidores de la quinasa dependiente de la ciclina. |
DE10037310A1 (de) * | 2000-07-28 | 2002-02-07 | Asta Medica Ag | Neue Indolderivate und deren Verwendung als Arzneimittel |
EP1313710A1 (en) * | 2000-08-31 | 2003-05-28 | Pfizer Products Inc. | Pyrazole derivatives and their use as protein kinase inhibitors |
US20020103185A1 (en) * | 2000-08-31 | 2002-08-01 | Sanner Mark A. | Pyrazole derivatives |
JP2004517840A (ja) * | 2000-11-27 | 2004-06-17 | フアルマシア・イタリア・エツセ・ピー・アー | フェニルアセトアミド−ピラゾール誘導体およびそれの抗腫瘍薬としての使用 |
US6455559B1 (en) * | 2001-07-19 | 2002-09-24 | Pharmacia Italia S.P.A. | Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents |
US20040116497A1 (en) * | 2001-01-26 | 2004-06-17 | Gabriella Traquandi | Chromane derivatives, process for their preparation and their use as antitumor agents |
JP2004526721A (ja) * | 2001-03-02 | 2004-09-02 | エフ.ホフマン−ラ ロシュ アーゲー | Ipアンタゴニストとしてのアルコキシカルボニルアミノヘテロアリールカルボン酸誘導体 |
SE0100903D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
SE0100902D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
US6787555B2 (en) | 2001-04-30 | 2004-09-07 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
US6727364B2 (en) | 2001-04-30 | 2004-04-27 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
US6890915B2 (en) | 2001-05-25 | 2005-05-10 | Bristol-Myers Squibb Pharma Company | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
DE10148618B4 (de) * | 2001-09-25 | 2007-05-03 | Schering Ag | Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel |
DE10148617A1 (de) * | 2001-09-25 | 2003-04-24 | Schering Ag | Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel |
US7087768B2 (en) * | 2001-09-27 | 2006-08-08 | Equispharm Co., Ltd. | Fumagillol derivatives and preparing method thereof |
SE0103710D0 (sv) | 2001-11-07 | 2001-11-07 | Astrazeneca Ab | Compounds |
US7514406B2 (en) * | 2001-11-27 | 2009-04-07 | Fred Hutchinson Cancer Research Center | Methods for inhibiting deacetylase activity |
SE0202539D0 (sv) | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
GB0221246D0 (en) * | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Compounds |
US6593477B1 (en) | 2002-10-29 | 2003-07-15 | Eastman Kodak Company | Synthesis of 3-acylaminopyrazoles |
WO2004052885A1 (en) * | 2002-12-10 | 2004-06-24 | Virochem Pharma Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
UA81790C2 (uk) | 2002-12-19 | 2008-02-11 | Фармация Италия С.П.А. | Заміщені піролопіразольні похідні як інгібітори кінази |
WO2004063194A1 (en) * | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | Heteroaryl compounds |
PL378117A1 (pl) * | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
WO2004087051A2 (en) * | 2003-03-27 | 2004-10-14 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
SE0301446D0 (sv) | 2003-05-16 | 2003-05-16 | Astrazeneca Ab | New Compounds |
UA80763C2 (en) | 2003-05-22 | 2007-10-25 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | |
JP4220548B2 (ja) | 2003-06-05 | 2009-02-04 | エラン ファーマシューティカルズ,インコーポレイテッド | アシル化されたアミノ酸・アミジルピラゾール、および関連化合物 |
US7141568B2 (en) | 2003-07-09 | 2006-11-28 | Pfizer Italia S.R.L. | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
BRPI0414313A (pt) | 2003-09-11 | 2006-11-07 | Kemia Inc | inibidores de citocinas |
US7399778B2 (en) * | 2004-01-16 | 2008-07-15 | Wyeth | Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole |
WO2005072731A1 (en) * | 2004-01-29 | 2005-08-11 | X-Ceptor Therapeutics, Inc. | 3-phenyl-n- ((1, 3, 4) thiadiazol-2-yl) -acrylamide derivatives and related compounds as modulators of estrogen-related receptors for the treatment of e.g. cancer, rheumatoid arthritis or neurological disorders |
AU2005210474B2 (en) * | 2004-01-30 | 2011-07-07 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding cassette transporters |
US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
TW200526204A (en) | 2004-02-03 | 2005-08-16 | Pharmacia Italia Spa | 1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors |
WO2005118543A1 (ja) * | 2004-06-03 | 2005-12-15 | Ono Pharmaceutical Co., Ltd. | キナーゼ阻害薬およびその用途 |
US7648992B2 (en) | 2004-07-05 | 2010-01-19 | Astrazeneca Ab | Hydantoin derivatives for the treatment of obstructive airway diseases |
SE0401762D0 (sv) * | 2004-07-05 | 2004-07-05 | Astrazeneca Ab | Novel compounds |
WO2006058923A1 (en) * | 2004-12-03 | 2006-06-08 | Novo Nordisk A/S | Heteroaromatic glucokinase activators |
SE0403086D0 (sv) | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Compounds |
SE0403085D0 (sv) | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Novel componds |
US7361672B2 (en) | 2004-12-23 | 2008-04-22 | Hoffmann-La Roche Inc. | Heteroarylacetamide inhibitors of factor Xa |
FR2880540B1 (fr) * | 2005-01-13 | 2008-07-11 | Aventis Pharma Sa | Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90 |
NZ564743A (en) * | 2005-07-11 | 2010-03-26 | Mitsubishi Tanabe Pharma Corp | An oxime derivative as a glucokinase activating agent and preparations thereof |
WO2007009898A1 (en) | 2005-07-19 | 2007-01-25 | Nerviano Medical Sciences S.R.L. | 1h-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors |
NZ566744A (en) * | 2005-08-29 | 2011-04-29 | Gerard M Housey | Theramutein modulators |
UY30048A1 (es) | 2005-12-23 | 2007-07-31 | Astrazeneca Ab | Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones |
WO2007081966A2 (en) * | 2006-01-09 | 2007-07-19 | University Of Southern California | Small molecules for treating cancer and abnormal cell proliferation disorders |
WO2007095383A2 (en) * | 2006-02-15 | 2007-08-23 | Myriad Genetics, Inc. | Prodrugs |
UY30183A1 (es) * | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
US8211925B2 (en) | 2006-04-28 | 2012-07-03 | Transtech Pharma, Inc. | Benzamide glucokinase activators |
EP2016068A1 (en) * | 2006-05-03 | 2009-01-21 | AstraZeneca AB | Pyrazole derivatives and their use as pi3k inhibitors |
JP2009543768A (ja) * | 2006-07-14 | 2009-12-10 | アステックス・セラピューティクス・リミテッド | 医薬組み合わせ |
TWI433839B (zh) | 2006-08-11 | 2014-04-11 | Neomed Inst | 新穎的苯并咪唑衍生物290 |
TW200831488A (en) * | 2006-11-29 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
US7737149B2 (en) * | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
US8314247B2 (en) | 2007-01-10 | 2012-11-20 | Mitsubishi Tanabe Pharma Corporation | Hydrazone derivative |
WO2008084873A1 (ja) * | 2007-01-10 | 2008-07-17 | Mitsubishi Tanabe Pharma Corporation | オキシム誘導体 |
US8940900B2 (en) * | 2007-02-28 | 2015-01-27 | Advinus Therapeutics Private Limited | 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application |
KR100923540B1 (ko) * | 2007-11-23 | 2009-10-27 | 한국과학기술연구원 | 5-아실하이드라진카르보닐-3,4-디치환 피라졸 유도체 및이의 제조방법 |
KR20110020904A (ko) * | 2008-06-19 | 2011-03-03 | 아스트라제네카 아베 | 피라졸 화합물 436 |
ES2622575T3 (es) * | 2008-07-10 | 2017-07-06 | General Incorporated Association Pharma Valley Project Supporting Organization | Inhibidor de STAT3 que contiene un derivado de quinolincarboxamida como ingrediente activo |
WO2010009985A2 (en) | 2008-07-24 | 2010-01-28 | Nerviano Medical Sciences S.R.L. | Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents |
US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
CR20160269A (es) * | 2008-12-05 | 2016-08-16 | Abbvie Inc | Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento del cancer y enfermedades comunes |
US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
BRPI1006896B1 (pt) * | 2009-01-30 | 2022-05-24 | Novartis Ag | Cloridrato de n-{(1s)-2-amino-1-[(3-fluorfenil)metil]etil}-5-cloro-4-(4-cloro-1-metil-1h- pirazol-5-il)-2-tiofenocarboxamida cristalino, composição farmacêutica compreendendo o mesmo e uso do dito composto para tratar ou diminuir a gravidade de câncer e artrite |
US20120045459A1 (en) * | 2009-05-05 | 2012-02-23 | Van Andel Research Institute | Methods for Treating Autophagy-Related Disorders |
CA2770454A1 (en) * | 2009-08-19 | 2011-02-24 | Ambit Biosciences Corporation | Biaryl compounds and methods of use thereof |
US9062076B2 (en) * | 2009-10-22 | 2015-06-23 | Fibrotech Therapeutics Pty Ltd | Fused ring analogues of anti-fibrotic agents |
CA2779681A1 (en) * | 2009-11-05 | 2011-05-12 | Lexicon Pharmaceuticals, Inc. | Tryptophan hydroxylase inhibitors for the treatment of cancer |
BR112012024678A2 (pt) | 2010-03-30 | 2016-06-07 | Verseon Corp | composto, composição farmacêutica, e, métodos para tratar e para previnir uma doença ou distúrbio |
SG186229A1 (en) | 2010-06-07 | 2013-01-30 | Novomedix Llc | Furanyl compounds and the use thereof |
EP2582666B1 (en) | 2010-06-16 | 2014-08-13 | Purdue Pharma L.P. | Aryl substituted indoles and their use as blockers of sodium channels |
EP2635278B1 (en) * | 2010-11-03 | 2019-12-11 | Dow AgroSciences LLC | Pesticidal compositions and processes related thereto |
JP6097998B2 (ja) * | 2010-12-16 | 2017-03-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ロイコトリエン生成のビアリールアミドインヒビター |
WO2012080990A1 (en) | 2010-12-17 | 2012-06-21 | Nerviano Medical Sciences S.R.L. | Substituted pyrazolo-quinazoline derivatives as kinase inhibitors |
FR2978441A1 (fr) * | 2011-07-25 | 2013-02-01 | Diverchim | Nouveaux analogues de ceramides, leurs procedes de preparation et leurs applications dans les compositions pharmaceutiques et cosmetiques |
AR087701A1 (es) * | 2011-08-31 | 2014-04-09 | Japan Tobacco Inc | Derivados de pirazol con actividad inhibidora de sglt1 |
ES2882807T3 (es) * | 2011-09-16 | 2021-12-02 | Novartis Ag | Heterociclil carboxamidas N-sustituidas |
CA2852688C (en) | 2011-10-26 | 2021-06-29 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
US9282739B2 (en) | 2012-04-27 | 2016-03-15 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
US8901153B2 (en) | 2012-04-27 | 2014-12-02 | Dow Agrosciences, Llc. | Pesticidal compositions and processes related thereto |
US9708288B2 (en) | 2012-04-27 | 2017-07-18 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
US20140179712A1 (en) | 2012-12-21 | 2014-06-26 | Astrazeneca Ab | Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide |
CN103936637B (zh) * | 2013-01-18 | 2016-04-06 | 北京大学 | E-3,4-二羟苯乙烯基亚砜类化合物的制备方法及其作为神经保护药物的应用 |
SG11201506695UA (en) | 2013-03-15 | 2015-09-29 | Glaxosmithkline Ip Dev Ltd | Pyridine derivatives as rearranged during transfection (ret) kinase inhibitors |
US8937071B2 (en) | 2013-03-15 | 2015-01-20 | Glaxosmithkline Intellectual Property Development Limited | Compounds as rearranged during transfection (RET) inhibitors |
MX2015011567A (es) | 2013-03-15 | 2016-04-25 | Verseon Corp | Halogeno-pirazoles como inhibidores de trombina. |
US9533970B2 (en) | 2013-03-15 | 2017-01-03 | Verseon Corporation | Multisubstituted aromatic compounds as serine protease inhibitors |
EP2996689A1 (en) * | 2013-04-17 | 2016-03-23 | Albert-Ludwigs-Universität Freiburg | Compounds for use as bromodomain inhibitors |
CN103265535B (zh) * | 2013-05-14 | 2015-06-17 | 浙江医药高等专科学校 | 抗肿瘤化合物、其制备方法和用途 |
EP3039021A1 (en) * | 2013-08-30 | 2016-07-06 | Ambit Biosciences Corporation | Biaryl acetamide compounds and methods of use thereof |
CN105636443A (zh) | 2013-10-17 | 2016-06-01 | 美国陶氏益农公司 | 制备杀虫化合物的方法 |
MX2016004942A (es) | 2013-10-17 | 2016-06-28 | Dow Agrosciences Llc | Procesos para la preparacion de compuestos plaguicidas. |
JP2016539095A (ja) | 2013-10-17 | 2016-12-15 | ダウ アグロサイエンシィズ エルエルシー | 有害生物防除性化合物の製造方法 |
KR20160075565A (ko) | 2013-10-17 | 2016-06-29 | 다우 아그로사이언시즈 엘엘씨 | 살충성 화합물의 제조 방법 |
US9044017B2 (en) | 2013-10-17 | 2015-06-02 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
JP2016535008A (ja) | 2013-10-17 | 2016-11-10 | ダウ アグロサイエンシィズ エルエルシー | 有害生物防除化合物の調製法 |
WO2015058024A1 (en) | 2013-10-17 | 2015-04-23 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
US9491944B2 (en) | 2013-10-22 | 2016-11-15 | Dow Agrosciences Llc | Pesticidal compositions and related methods |
EP3094183A4 (en) | 2013-10-22 | 2017-08-09 | Dow AgroSciences LLC | Synergistic pesticidal compositions and related methods |
JP6490681B2 (ja) | 2013-10-22 | 2019-03-27 | ダウ アグロサイエンシィズ エルエルシー | 農薬組成物および関連する方法 |
US9549560B2 (en) | 2013-10-22 | 2017-01-24 | Dow Agrosciences Llc | Pesticidal compositions and related methods |
CA2926647A1 (en) | 2013-10-22 | 2015-04-30 | Dow Agrosciences Llc | Pesticidal compositions and related methods |
AU2014340409B2 (en) | 2013-10-22 | 2017-09-07 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
US9295258B2 (en) | 2013-10-22 | 2016-03-29 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
WO2015061175A1 (en) | 2013-10-22 | 2015-04-30 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
CA2927202A1 (en) | 2013-10-22 | 2015-04-30 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
WO2015061151A1 (en) | 2013-10-22 | 2015-04-30 | Dow Agrosciences Llc | Pesticidal compositions and related methods |
CN105828612A (zh) | 2013-10-22 | 2016-08-03 | 美国陶氏益农公司 | 协同杀虫组合物和相关方法 |
KR20160074585A (ko) | 2013-10-22 | 2016-06-28 | 다우 아그로사이언시즈 엘엘씨 | 상승작용적 살충 조성물 및 관련 방법 |
CN105828611A (zh) | 2013-10-22 | 2016-08-03 | 美国陶氏益农公司 | 协同杀虫组合物和相关方法 |
AU2014340413B2 (en) | 2013-10-22 | 2017-09-07 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
AR098093A1 (es) | 2013-10-22 | 2016-05-04 | Dow Agrosciences Llc | Composiciones pesticidas sinérgicas y métodos relacionados |
NZ719759A (en) | 2013-10-22 | 2017-05-26 | Dow Agrosciences Llc | Pesticidal compositions and related methods |
AU2014340443B2 (en) | 2013-10-22 | 2017-06-08 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
WO2015143653A1 (en) * | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
JP2017523168A (ja) | 2014-07-31 | 2017-08-17 | ダウ アグロサイエンシィズ エルエルシー | 3−(3−クロロ−1h−ピラゾール−1−イル)ピリジンの製造方法 |
WO2016018444A1 (en) | 2014-07-31 | 2016-02-04 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine |
CA2954345A1 (en) | 2014-07-31 | 2016-02-04 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine |
KR20170042714A (ko) | 2014-08-19 | 2017-04-19 | 다우 아그로사이언시즈 엘엘씨 | 3-(3-클로로-1h-피라졸-1-일)피리딘의 제조 방법 |
PT3191450T (pt) | 2014-09-10 | 2019-05-29 | Glaxosmithkline Ip Dev Ltd | Derivados de piridona como inibidores da quinase rearranjada durante a transfecção (ret) |
KR20170046180A (ko) | 2014-09-10 | 2017-04-28 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 형질감염 중 재배열 (ret) 억제제로서의 신규 화합물 |
KR20170058388A (ko) | 2014-09-12 | 2017-05-26 | 다우 아그로사이언시즈 엘엘씨 | 3-(3-클로로-1h-피라졸-1-일)피리딘의 제조 방법 |
RU2017112739A (ru) | 2014-09-17 | 2018-10-17 | Версеон Корпорейшн | Пиразолил-замещенные пиридоновые соединения как ингибиторы сериновых протеаз |
GB201416513D0 (en) * | 2014-09-18 | 2014-11-05 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
SG10201907699YA (en) | 2015-02-27 | 2019-09-27 | Verseon Corp | Substituted pyrazole compounds as serine protease inhibitors |
CA2978170C (en) | 2015-03-09 | 2024-02-27 | Aurigene Discovery Technologies Limited | Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors |
CN107847495A (zh) | 2015-05-06 | 2018-03-27 | 加利福尼亚大学董事会 | K‑Ras调节剂 |
AU2016272908B2 (en) | 2015-06-04 | 2021-05-06 | Aurigene Oncology Limited | Substituted heterocyclyl derivatives as CDK inhibitors |
CN110023310B (zh) * | 2016-08-12 | 2024-05-10 | 阿西纳斯公司 | 用于调节激酶级联的联芳组合物和方法 |
CN110325036B (zh) | 2016-12-29 | 2021-10-26 | 美国陶氏益农公司 | 用于制备杀虫化合物的方法 |
KR20190098204A (ko) * | 2016-12-29 | 2019-08-21 | 엔요 파마 | 항바이러스제로서의 티오펜 유도체 |
JP2020503336A (ja) | 2016-12-29 | 2020-01-30 | ダウ アグロサイエンシィズ エルエルシー | 殺有害生物化合物の調製方法 |
JP7185631B2 (ja) | 2017-02-03 | 2022-12-07 | サータ セラピューティクス プロプライエタリー リミテッド | 抗線維化化合物 |
SG11201908569QA (en) * | 2017-03-21 | 2019-10-30 | Arbutus Biopharma Corp | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same |
US11358940B2 (en) | 2017-04-20 | 2022-06-14 | The Regents Of The University Of California | K-Ras modulators |
TWI828644B (zh) | 2017-12-06 | 2024-01-11 | 仁新醫藥股份有限公司 | 微管蛋白抑制劑 |
AU2019215799B2 (en) * | 2018-02-01 | 2022-04-14 | The University Of Sydney | Anti-cancer compounds |
AU2019247885B2 (en) * | 2018-04-04 | 2023-09-07 | Aurigene Oncology Limited | Substituted pyrazole derivatives as selective CDK12/13 inhibitors |
CN114040760A (zh) | 2018-12-31 | 2022-02-11 | 拜欧米富士恩公司 | Menin-mll相互作用的不可逆抑制剂 |
WO2020142559A1 (en) | 2018-12-31 | 2020-07-09 | Biomea Fusion, Llc | Inhibitors of menin-mll interaction |
AU2021213257A1 (en) * | 2020-01-29 | 2022-08-25 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
CN111793034B (zh) * | 2020-07-24 | 2021-11-19 | 华中科技大学 | 苯并咪唑盐衍生物与制备抗肿瘤药物的应用 |
US20240132485A1 (en) * | 2020-10-16 | 2024-04-25 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof |
TW202229268A (zh) * | 2020-12-22 | 2022-08-01 | 大陸商上海拓界生物醫藥科技有限公司 | Cdk2抑制劑及其製備方法 |
IL310717A (en) | 2021-08-20 | 2024-04-01 | Biomea Fusion Inc | Crystalline form of N-[4-[4-(4-morpholinyl)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO ] -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, IRREVERSIBLE MENIN-MLL INHIBITOR FOR CANCER TREATMENT |
AU2022407173A1 (en) * | 2021-12-10 | 2024-06-27 | Prothena Biosciences Limited | Heterocyclic compounds as dyrk1a inhibitors |
WO2023203172A1 (en) * | 2022-04-20 | 2023-10-26 | Proxygen Gmbh | Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof |
CN116496151B (zh) * | 2023-04-26 | 2024-08-23 | 长沙医学院 | 一种利用Catellani策略制备芴酮衍生物的方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5162360A (en) | 1991-06-24 | 1992-11-10 | Warner-Lambert Company | 2-heteroatom containing urea and thiourea ACAT inhibitors |
DE69532817T2 (de) | 1994-11-10 | 2005-01-13 | Millenium Pharmaceuticals, Inc., Cambridge | Verwendung von pyrazole verbindungen zur behandlung von glomerulonephritis, krebs, atherosklerose oder restenose |
US6043246A (en) | 1996-12-03 | 2000-03-28 | Banyu Pharmaceutical Co., Ltd. | Urea derivatives |
CA2288787A1 (en) | 1997-05-22 | 1998-11-26 | G.D. Searle And Co. | Pyrazole derivatives as p38 kinase inhibitors |
BR9814361A (pt) | 1997-12-22 | 2001-11-27 | Bayer Ag | Inibição de quinase raf usando uréiasheterocìclicas substituìdas por arila eheteroarila |
CA2315720A1 (en) | 1997-12-22 | 1999-07-01 | Bayer Corporation | Inhibition of p38 kinase activity using substituted heterocyclic ureas |
OA12046A (en) * | 1999-08-12 | 2006-05-02 | Pharmacia Italia Spa | 3(5)-Amino-pyrazole derivatives, process for theirpreparation and their use as antitumor agents. |
US6455559B1 (en) * | 2001-07-19 | 2002-09-24 | Pharmacia Italia S.P.A. | Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents |
-
2000
- 2000-05-05 OA OA1200200051A patent/OA12046A/en unknown
- 2000-05-05 EA EA200200248A patent/EA005373B1/ru not_active IP Right Cessation
- 2000-05-05 GE GE4758A patent/GEP20053476B/en unknown
- 2000-05-05 HU HU0203542A patent/HUP0203542A3/hu unknown
- 2000-05-05 IL IL14792300A patent/IL147923A0/xx unknown
- 2000-05-05 NZ NZ517237A patent/NZ517237A/xx unknown
- 2000-05-05 CN CN00812732A patent/CN1373662A/zh active Pending
- 2000-05-05 PL PL00353455A patent/PL353455A1/xx not_active Application Discontinuation
- 2000-05-05 ES ES00931906T patent/ES2249270T3/es not_active Expired - Lifetime
- 2000-05-05 AU AU49714/00A patent/AU4971400A/en not_active Abandoned
- 2000-05-05 US US10/048,486 patent/US7034049B1/en not_active Expired - Fee Related
- 2000-05-05 KR KR1020027001857A patent/KR20020060160A/ko not_active Application Discontinuation
- 2000-05-05 AT AT00931906T patent/ATE305782T1/de not_active IP Right Cessation
- 2000-05-05 CA CA002383555A patent/CA2383555C/en not_active Expired - Fee Related
- 2000-05-05 DE DE60023012T patent/DE60023012T2/de not_active Expired - Fee Related
- 2000-05-05 EE EEP200200065A patent/EE200200065A/et unknown
- 2000-05-05 MX MXPA02001498A patent/MXPA02001498A/es active IP Right Grant
- 2000-05-05 AP APAP/P/2002/002442A patent/AP2002002442A0/en unknown
- 2000-05-05 CZ CZ2002422A patent/CZ2002422A3/cs unknown
- 2000-05-05 WO PCT/US2000/006699 patent/WO2001012189A1/en active IP Right Grant
- 2000-05-05 JP JP2001516535A patent/JP2003507329A/ja not_active Withdrawn
- 2000-05-05 SK SK181-2002A patent/SK1812002A3/sk unknown
- 2000-05-05 DK DK00931906T patent/DK1202733T3/da active
- 2000-05-05 EP EP00931906A patent/EP1202733B1/en not_active Expired - Lifetime
- 2000-05-05 BR BR0013143-1A patent/BR0013143A/pt not_active Application Discontinuation
- 2000-05-05 YU YU9602A patent/YU9602A/sh unknown
- 2000-05-15 PE PE2000000453A patent/PE20010130A1/es not_active Application Discontinuation
- 2000-05-16 AR ARP000102347A patent/AR026122A1/es unknown
- 2000-09-22 US US09/667,603 patent/US6218418B1/en not_active Expired - Fee Related
-
2002
- 2002-02-11 NO NO20020684A patent/NO20020684L/no not_active Application Discontinuation
- 2002-02-11 IS IS6265A patent/IS6265A/is unknown
- 2002-02-12 HR HR20020128A patent/HRP20020128A2/hr not_active Application Discontinuation
- 2002-02-22 ZA ZA200201511A patent/ZA200201511B/xx unknown
- 2002-03-05 BG BG06480A patent/BG106480A/xx unknown
- 2002-03-11 MA MA26549A patent/MA25493A1/fr unknown
- 2002-11-26 HK HK02108532.6A patent/HK1046866A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1202733T3 (da) | 3(5)-amino-pyrazolderivater, fremgangsmåde til deres fremstilling og deres anvendelse som antitumormidler | |
NO20012058D0 (no) | 2-ureido-tiazolderivater, fremgangsmåte for deres fremstilling og anvendelse som antitumormidler | |
NO20020687L (no) | 3(5)-ureido-pyrazolderivater, fremgangsmåte for fremstilling av disse og deres anvendelse som antitumormidler | |
NO20012057L (no) | 2-amino-tiazolderivater, fremgangsmåte for deres fremstilling og anvendelse som antitumormidler | |
NO963506D0 (no) | 4-Heterocyklyl-substituerte kinazolin-derivater, fremgangsmåte for fremstilling derav og deres anvendelse som anti-kreftmidler | |
NO20015477D0 (no) | 4,5,6,7-tetrahydroindazol-derivater som anti-tumor midler | |
DK1204649T3 (da) | Arylmethylcarbonylaminothiazolderivater og deres anvendelse som antitumormidler | |
DK1218341T3 (da) | Sulfonylcarboxamid-derivater, fremgangsmåde til deres fremstilling og deres anvendelse som lægemiddel | |
NO20014013D0 (no) | 16-halogenepotilonderivater, fremgangsmater for fremstilling av dem og deres farmasoytiske anvendelse | |
NO20006029L (no) | Pyrazolinderivater, deres fremstilling og anvendelse som legemidler | |
NO993003D0 (no) | Sulfonamid-derivater, fremgangsmÕte for deres fremstilling og deres anvendelse som medikamenter | |
DK0740668T3 (da) | Tetracykliske derivater, fremgangsmåde til deres fremstilling og deres anvendelse | |
NO20016038L (no) | Benzenderivater, fremgangsmåte for deres fremstilling og farmasöytiske preparater inneholdende de samme | |
NO20011503D0 (no) | Indeno-, nafto- og benzocyklohepta-dihydrotiazolderivater, deres fremstilling og anvendelse som anorektiske legemidler | |
DK1095025T3 (da) | Benzimidazoler, deres fremstilling og deres anvendelse som lægemidler | |
NO20005146L (no) | Tienylazolylalkoksyetanaminer, deres fremstilling og deres anvendelse som medikamenter | |
DK0915845T3 (da) | Acryloylsubstituerede distamycinderivater, fremgangsmåde til fremstilling deraf og anvendelse som antitumormidler og antivirale midler | |
DK0912509T3 (da) | Distamycinderivater, fremgangsmåde til fremstilling deraf og deres anvendelse som antitumor- og antivirale midler | |
NO20040210L (no) | Fenylacetamido-tiazolderivater, fremgangsmate for deres fremstilling og deres anvendelse som antitumormidler | |
NO20010219L (no) | Polycykliske tiazolidin-2-ylidenaminer, fremgangsmÕte for deres fremstilling og deres anvendelse som legemiddel | |
NO20016404L (no) | Naftyridinderivater, fremgangsmåter for deres fremstilling, deres anvendelse og farmasöytiske preparater omfattende disse | |
DK1157020T3 (da) | Substituerede 1,2,3,4,5,6-hexahydro-2,6-methano-2-benzazocin-10-oler, fremgangsmåder til deres fremstilling og deres anvendelse som lægemiddel | |
NO20002959D0 (no) | Echinocandinderivater, fremgangsmÕte for fremstilling av slike og deres anvendelse som anti-soppmidler | |
DK1157014T3 (da) | Polycykliske 2-amino-dihydrothiazolsystemer, fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler | |
DK1124810T3 (da) | 2-amino-thiazolderivater, fremgangsmåde til deres fremstilling og deres anvendelse som antitumormidler |